首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Role of HIV membrane in neutralization by two broadly neutralizing antibodies
【24h】

Role of HIV membrane in neutralization by two broadly neutralizing antibodies

机译:HIV膜在两种广泛中和抗体中和中的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Induction of effective antibody responses against HIV-1 infection remains an elusive goal for vaccine development. Progress may require in-depth understanding of the molecular mechanisms of neutralization by monoclonal antibodies. We have analyzed the molecular actions of two rare, broadly neutralizing, human monoclonal antibodies, 4E10 and 2F5, which target the transiently exposed epitopes in the membrane proximal external region (MPER) of HIV-1 gp41 envelope during viral entry. Both have long CDR H3 loops with a hydrophobic surface facing away from the peptide epitope. We find that the hydrophobic residues of 4E10 mediate a reversible attachment to the viral membrane and that they are essential for neutralization, but not for interaction with gp41. We propose that these antibodies associate with the viral membrane in a required first step and are thereby poised to capture the transient gp41 fusion intermediate. These results bear directly on strategies for rational design of HIV-1 envelope immunogens.
机译:诱导针对HIV-1感染的有效抗体反应仍然是疫苗开发的目标。进展可能需要深入了解单克隆抗体中和的分子机制。我们已经分析了两种罕见的,广泛中和的人类单克隆抗体4E10和2F5的分子作用,它们在病毒进入过程中靶向HIV-1 gp41包膜的膜近端外部区域(MPER)中的瞬时暴露表位。两者均具有长的CDR H3环,疏水表面背离肽表位。我们发现4E10的疏水残基介导可逆的附着到病毒膜,并且它们对于中和是必不可少的,但对于与gp41的相互作用不是必需的。我们建议这些抗体在所需的第一步中与病毒膜结合,从而准备捕获瞬时gp41融合中间体。这些结果直接关系到合理设计HIV-1包膜免疫原的策略。

著录项

  • 来源
  • 作者单位

    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710;

    Laboratory of Molecular Medicine, Children's Hospital, 320 Longwood Avenue, Boston, MA 02115 Program in Virology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115;

    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710;

    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710;

    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710;

    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710;

    Laboratory of Molecular Medicine, Children's Hospital, 320 Longwood Avenue, Boston, MA 02115 Howard Hughes Medical Institute, 320 Longwood Avenue, Boston, MA 02115;

    Xiamen Amoytop Biotech Company, Ltd., 330 Wengjiao Road, Xiamen, Fujian, China 361022;

    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710 Howard Hughes Medical Institute, 320 Longwood Avenue, Boston, MA 02115 Department of Pediatrics, Harvard Medical School, 320 Longwood Avenue, Boston, MA 02115;

    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710;

    Laboratory of Molecular Medicine, Children's Hospital, 320 Longwood Avenue, Boston, MA 02115 Department of Pediatrics, Harvard Medical School, 320 Longwood Avenue, Boston, MA 02115;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    gp41; MPER;

    机译:gp41;MPER;
  • 入库时间 2022-08-18 00:42:10

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号